According to a study, venetoclax plus hypomethylating agent is effective in newly diagnosed acute myeloid leukemia, and safe in an outpatient setting. So the statement is true.
<h3>What is venetoclax?</h3>
Venetoclax is either used alone or in combination with another drug called obinutuzumab or rituximab. This is used for the treatment of certain types of chronic lymphocytic leukemia. It is a type of cancer that develops in white blood cells. It is also used for certain types of small lymphocytic lymphoma, which is a type of cancer that develops in the lymph nodes.
It can also be used in combination with either azacitidine, decitabine, or cytarabine. This is done as the initial treatment for acute myeloid leukemia, which is a type of cancer that begins in the white blood cells in people who are 75 years or older. It can also develop in adults having medical conditions that prevent them from being treated with any other treatment than chemotherapy medications.
The class of medications from which Venetoclax belongs is called B-cell lymphoma-2 inhibitors. These medicines work by blocking the action of a particular protein in the body that promotes cancer cells' survival. This helps in killing cancer cells.
Therefore, the statement is true.
Read more about leukemia, here
brainly.com/question/5868856
#SPJ4
